Antibody Therapeutic Patents

Antibody therapeutic patents cover antibody-discovery-platform innovations (humanization, phage display, transgenic mice); antibody-sequence and epitope composition-of-matter; format innovations (bispecific, antibody-drug conjugate, Fc engineering); and formulation and manufacturing innovations — with IP held by large-cap biopharma and antibody-engineering specialists. MAJOR ANTIBODY PATENT HOLDERS: ABBVIE (Humira/adalimumab anti-TNF): the canonical 'patent thicket' — 100+ patents on formulation (high-concentration, citrate-free), manufacturing, and indications layered to extend exclusivity well past the composition-of-matter expiry. ROCHE / GENENTECH (300+): Herceptin/trastuzumab (HER2), Avastin/bevacizumab (VEGF), Rituxan/rituximab (CD20), Perjeta, and the foundational humanization (CDR-grafting) heritage. MERCK (Keytruda/pembrolizumab): anti-PD-1 checkpoint inhibitor, one of the largest-selling drugs, deep patent estate. BRISTOL MYERS SQUIBB: Opdivo/nivolumab (PD-1), Yervoy/ipilimumab (CTLA-4). REGENERON (200+): VelocImmune transgenic-mouse fully-human-antibody platform, Dupixent/dupilumab (IL-4Rα), Eylea/aflibercept (trap). OTHERS: Amgen, Johnson & Johnson, AstraZeneca, Sanofi, and platform owners — Cambridge Antibody/MedImmune (phage display), Abgenix XenoMouse and Medarex UltiMab (transgenic-mouse fully-human antibodies, now Amgen/BMS).

Humanization (CDR-grafting) innovations; display-technology (phage, yeast, mammalian) innovations; transgenic-animal fully-human-antibody innovations; and single-B-cell and library innovations represent core antibody-discovery patent domains. HUMANIZATION PATENTS: CDR-grafting (transplanting murine complementarity-determining regions onto a human framework — Winter's foundational work), framework back-mutation/resurfacing, and de-immunization to reduce anti-drug-antibody response (the Queen/PDL humanization patents were among the most-licensed in biotech). DISPLAY PATENTS: phage display (antibody libraries displayed on bacteriophage, panned against antigen — Greg Winter and George Smith shared the 2018 Nobel Prize in Chemistry; the McCafferty/Cambridge Antibody patents drove a generation of licensing), yeast display, ribosome/mRNA display, and mammalian display. TRANSGENIC-ANIMAL PATENTS: mice engineered with human immunoglobulin loci producing fully-human antibodies — XenoMouse (Abgenix), HuMAb-Mouse/UltiMab (Medarex), VelocImmune (Regeneron), OmniRat/OmniMouse — these platforms are themselves heavily patented and the source of many marketed antibodies. LIBRARY / SINGLE-CELL PATENTS: naive/synthetic/immune library construction, single-B-cell antibody cloning, and high-throughput screening. Discovery-platform IP is durable because it gates how new antibodies are made; the resulting molecule then gets its own composition-of-matter protection.

Antibody-format innovations; Fc-engineering innovations; antibody-drug-conjugate innovations; and sequence/epitope composition-of-matter claims represent additional antibody patent domains — and the antibody sequence itself is the core durable asset. FORMAT PATENTS: bispecific antibodies (BiTE T-cell-engager like blinatumomab, DART, knobs-into-holes heavy-chain heterodimerization, CrossMab correct light-chain pairing, common-light-chain), fragments (Fab, scFv, single-domain VHH nanobody from camelids — Ablynx/caplacizumab), and multispecifics. FC-ENGINEERING PATENTS: ADCC/CDC enhancement (afucosylation, amino-acid mutations for FcγR binding), half-life extension via FcRn-binding mutations (YTE: M252Y/S254T/T256E; LS: M428L/N434S), effector-function silencing (IgG4, LALA), and isotype selection. ADC PATENTS: antibody-drug conjugates — linker chemistry (cleavable valine-citrulline, non-cleavable), cytotoxic payloads (MMAE/MMAF auristatins, DM1/DM4 maytansinoids, DXd/exatecan topoisomerase — Enhertu, calicheamicin), and conjugation site/DAR (drug-antibody ratio) control (site-specific, engineered cysteine). COMPOSITION-OF-MATTER: the patentable core is the antibody sequence — claimed by the six CDR sequences (and often the variable regions), plus functional/epitope claims (binds a defined epitope, competes with a reference antibody); these give the same ~20-year composition-of-matter protection any new molecule receives.

Antibody therapeutic startup IP strategy must navigate AbbVie-style formulation/manufacturing patent thickets, Roche/Genentech humanization and target patents, platform patents on phage display and transgenic mice (often requiring a license), checkpoint-target estates (PD-1/PD-L1/CTLA-4), the BPCIA biosimilar 'patent dance,' and recent enablement law (Amgen v. Sanofi, 2023) that limits broad functional/genus antibody claims; understand that the durable asset is the specific antibody sequence (six CDRs) plus formats and formulations, that broad 'any antibody that binds epitope X' genus claims are now hard to enforce after Amgen v. Sanofi, and that discovery-platform freedom-to-operate (which display/transgenic platform you use) is a gating licensing question; identify whitespace in novel targets, bispecific/multispecific formats, next-generation ADC payloads/linkers, and half-life-extended Fc variants. ANTIBODY-THERAPEUTIC STARTUP IP STRATEGY: SEQUENCE + FORMAT + FORMULATION ARE THE IP — BROAD GENUS CLAIMS ARE NOW WEAK: patent the specific CDR sequences, the format (bispecific/ADC), and formulation; after Amgen v. Sanofi (S.Ct. 2023) a functional genus ('any antibody binding epitope X and blocking Y') likely fails enablement — claim what you actually made and characterized; PLATFORM FREEDOM-TO-OPERATE IS A LICENSING QUESTION: phage-display and transgenic-mouse platforms are patented — secure FTO/a license for your discovery platform before you scale; ADC PAYLOADS/LINKERS AND MULTISPECIFICS ARE HIGHEST-VALUE WHITESPACE: novel linker-payload chemistry, site-specific conjugation, and correctly-paired bispecifics are the most active patenting terrain; BPCIA/PATENT-THICKET AWARENESS: incumbents layer formulation/manufacturing/indication patents to extend exclusivity — map the thicket before a biosimilar or a me-better; WHEN TO PATENT: NOVEL ANTIBODY WITH MEASURED BINDING/FUNCTION: file composition-of-matter once a lead is sequenced and characterized (CDRs + affinity KD + epitope + functional potency EC50 + developability) — measured affinity, epitope, potency, and developability are the critical antibody IP metrics; KEY FTO CHECKLIST: humanization CDR-grafting (Queen/PDL); phage display (Cambridge Antibody/McCafferty); transgenic mouse XenoMouse/VelocImmune/UltiMab; knobs-into-holes CrossMab common-light-chain bispecific; BiTE T-cell engager; ADC valine-citrulline MMAE DM1 DXd DAR site-specific; Fc YTE/LS half-life afucosylation ADCC; VHH nanobody; Amgen v. Sanofi enablement on genus claims; BPCIA patent dance; high-concentration citrate-free formulation thicket.